Use of ACE-inhibitors and Quality of Life in an Older Population - 06/12/24
, P. Finamore 1, A. Gemma 3, R. Bernabei 2, R.A. Incalzi 1, G. Zuccalà 2
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Improved ability to treat chronic diseases have increased the interest in measuring health-related quality of life (HRQoL) in older adults. Hypertension and heart failure have been associated with decreased HRQoL.
Hypothesis |
The aim of this study was to assess the association between health-related quality of life and use of angiotensin converting enzyme inhibitors in unselected community-dwelling elderly.
Methods |
We analyzed data of all 387 subjects aged 75+ living in a rural Italian town, without exclusion criteria. HRQoL was assessed using the Health Utility Index Mark 3, which allows formal cost-effectiveness calculations. The association of the HRQoL score with use of ACE-I was analyzed by multivariable linear and logistic regression.
Results |
The median HUI3 score was 0.31, and 186 participants (48%) reported a score above the median value. Use of ACE-I was reported by 34 (9%) participants, and confirmed by general practitioners. Use of these agents was associated with significantly better HRQoL (B=.16, 95% CI=.02 -.30; P=.025). Also, use of ACE-I was associated with increased probability of better HRQoL in logistic regression (OR=2.83; 95% CI=1.03 - 7.78; P=.044) after adjusting. No associations were found between the HRQoL score and use of calcium antagonists or beta-blockers.
Conclusions |
Use of ACE-I, but not of other antihypertensives, is associated with better HRQoL among community-dwelling older adults. ACE-inhibitors might therefore present with the best cost-effectiveness ratio for the treatment of older populations.
Le texte complet de cet article est disponible en PDF.Key words : ACE-inhibitors, quality of life, elderly
Plan
Vol 22 - N° 10
P. 1162-1166 - décembre 2018 Retour au numéro
Article précédent
- International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management
- Elsa Dent, J.E. Morley, A.J. Cruz-Jentoft, H. Arai, S.B. Kritchevsky, J. Guralnik, J.M. Bauer, M. Pahor, B.C. Clark, M. Cesari, J. Ruiz, C.C. Sieber, M. Aubertin-Leheudre, D.L. Waters, R. Visvanathan, F. Landi, D.T. Villareal, R. Fielding, C.W. Won, O. Theou, F.C. Martin, B. Dong, J. Woo, L. Flicker, L. Ferrucci, R.A. Merchant, L. Cao, T. Cederholm, S.M.L. Ribeiro, L. Rodríguez-Mañas, S.D. Anker, J. Lundy, L.M. Gutiérrez Robledo, I. Bautmans, I. Aprahamian, J.M.G.A. Schols, M. Izquierdo, B. Vellas
- Normative Values of Muscle Power using Force Plate Jump Tests in Men Aged 77–101 Years: The Osteoporotic Fractures in Men (MrOS) Study
- Elsa S. Strotmeyer, M.E. Winger, J.A. Cauley, R.M. Boudreau, D. Cusick, R.F. Collins, D. Chalhoub, B. Buehring, E. Orwoll, T.B. Harris, P. Caserotti, Osteoporotic Fractures in Men (MrOS) Research Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.